Eurofins Scientific stock
Price history
+48.66% over the period1 year: from €57.38 (November 20, 2025) to €85.30 (November 20, 2026), +48.66%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €85.30 |
| October 30, 2026 | €87.72 |
| September 30, 2026 | €75.00 |
| August 31, 2026 | €72.54 |
| July 31, 2026 | €68.16 |
| June 30, 2026 | €68.56 |
| May 29, 2026 | €62.46 |
| April 30, 2026 | €59.02 |
| March 31, 2026 | €62.66 |
| February 27, 2026 | €68.16 |
| January 30, 2026 | €68.14 |
| December 31, 2025 | €62.40 |
| November 28, 2025 | €58.64 |
| November 20, 2025 | €57.38 |
At a glance
The company
Provides analytical testing and laboratory services across agroscience, food, biopharma, environmental, consumer products, and forensic sectors globally
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Eurofins Scientific
- Pricier than usual relative to earnings: P/E on the latest fiscal year 38 vs a median of 32 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 30 vs 32 (−7%) in a group of 10.
- Strong point: Market momentum (94/100 in its group). Weak point: Profitability (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.46% from the 52-week high
Analysts · 14 analysts
Average target€74.78−12.33% vs. price
Buy 3 · Hold 8 · Sell 3 · Hold
TickerLandia Fingerprint: Eurofins Scientific
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow31
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 29.6 35 Forward P/E 18.0 34 EV/EBITDA 12.2 22 Price/book 4.09 48 Price/sales 1.98 17 Profitabilitylow33
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 14.1% 28 Gross margin 23.1% 2 Net margin 7.2% 35 ROE 11.3% 44 ROA 6.0% 54 Earnings stabilityaverage56
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.5% 50 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthaverage42
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +2.50% 17 Earnings growth (year over year) +28.40% 58 Average revenue growth (3 years) +2.82% 50 Financial strengthlow33
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.96 20 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.33 42 Interest coverage 6.26 48 Current ratio 1.13 20 Dividendlow39
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.8% 50 Consecutive dividend years 6 years 32 Payout ratio 25.0% 34 Market momentumvery strong94
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +48.66% 89 Distance from 200-day average +22.22% 94 Relative strength (3 months) +24.90% 96 Relative strength (6 months) +40.60% 97 Risklow36
How much the price swings.
Metric Value Position in group Volatility (60 days) 21.9% 26 Maximum drawdown (12 months) 21.3% 37 Beta (1 year) 0.67 43
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Eurofins Scientific is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Eurofins Scientific's P/E today is 38.3, above the median of its last 10 fiscal years (31.6; between 23.0 and 63.4 from 2016 to 2025). Eurofins Scientific's P/E (trailing 12 months): 29.6, −7% against the median of a group of 10 similar companies (31.8).
Compared with 10 similar companies
| Metric | Eurofins Scientific | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 29.6 | Middle | |
| Forward P/E | 18.0 | Middle | |
| Operating margin | 14.1% | Low | |
| ROE | 11.3% | Middle | |
| Debt/equity | 0.96 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Eurofins Scientific. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€3.7B
Latest quarter · Q2 2026
Net income
€301.4M
Latest quarter · Q2 2026
Quarterly net margin
8.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €14.59B
- P/E
- 29.6
- EPS
- €2.88
- Volume
- 308.25K
- Daily trading
- €24.27M
- Dividend yield
- 0.84%
- Last ex-dividend on April 28, 2026
How Eurofins Scientific is changing
All resultsRevenue grew 6.1% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 172% of net income
Shares outstanding down 4.8% in 5 years
Returns
Eurofins Scientific returns with dividends
€1,000 invested in Eurofins Scientific 5 years ago, on November 22, 2021, would be worth €842 today with dividends reinvested: −15.79% in total, −3.38% per year. On price alone it would be €789 (−21.09%).
| Period | Eurofins Scientific | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +7.97% | +1.14% | €1,080 |
| 6 months | +37.31% | −2.34% | €1,373 |
| Year to date | +36.70% | −2.72% | €1,367 |
| 1 year | +50.45% | −0.67% | €1,504 |
| 3 years | +71.74% | +9.39% | €1,717 |
| 5 years | −15.79% | +11.58% | €842 |
| 10 years | +119.20% | +75.02% | €2,192 |
Over the last 6 months it has done better than 97% of the stocks in the Industrials sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
Eurofins Scientific: technical analysis
Eurofins Scientific is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 32.5% below its all-time closing high (€126.44, September 21, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- +22.22%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 18, 2026
Support and resistance
Price areas where Eurofins Scientific has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€85.30
- Support€74.57−12.58%3 touches, last on September 3, 2026
- Support€70.21−17.69%3 touches, last on July 7, 2026
- Support€68.57−19.61%3 touches, last on September 8, 2026
Volatility and risk
Over the last year it has moved less than the CAC 40.
- Beta (1 year) vs CAC 40
- 0.67
- Volatility (60 sessions, annualised)
- 21.9%
- Largest fall in the last year
- −21.31%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Eurofins Scientific: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for Eurofins Scientific has been April: +5.89% on average, positive in 23 years out of 29. The weakest has been December: +0.46% on average, positive in 17 years out of 29. November, the current month, has been positive in 16 years out of 29 (+4.62% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.95% | +3.43% | 16 of 29 |
| February | +4.71% | +1.99% | 17 of 29 |
| March | +0.62% | +0.78% | 15 of 29 |
| April | +5.89% | +2.86% | 23 of 29 |
| May | +0.57% | −0.20% | 14 of 29 |
| June | +1.79% | −0.97% | 13 of 29 |
| July | +1.71% | +0.55% | 15 of 29 |
| August | +1.25% | 0.00% | 14 of 29 |
| September | +2.49% | 0.00% | 14 of 29 |
| October | +3.57% | +1.24% | 17 of 29 |
| November | +4.62% | +3.56% | 16 of 29 |
| December | +0.46% | +2.62% | 17 of 29 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Eurofins Scientific and its competitors
Eurofins Scientific SE serves pharmaceutical and biotech companies, food and agriculture producers, consumer goods brands, environmental authorities and industrial clients across the world, offering analytical testing and laboratory services. Its work covers food and feed testing, environmental analysis of water, air, soil and waste, agroscience and seed services, consumer product and cosmetics testing, electrical and electronics laboratories, clinical and in vitro diagnostics, forensic and genomic services, and REACH chemical compliance. Its operations span many countries, and the company was founded in 1987.
- Headquarters
- Luxembourg, Luxembourg
- Employees
- 65,000
- Founded
- 1987
- Chief executive
- Gilles Martin
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Eurofins ScientificERF | $16.03B | 14.1% | 29.6 | +37.31% |
| bioMérieuxBIM | $11.82B | 16.0% | 23.4 | +25.67% |
| QiagenQIA | $10.23B | 26.7% | 28.5 | +50.69% |
| Lonza GroupLONN | $54.2B | 23.5% | 43.2 | +32.22% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
Same industry or related industries, similar size. Compare Eurofins Scientific with its competitors · Full profile
